Biohacking peptides and methylene blue

1. Introduction

Version followed: there is no founder, manual or originating organisation. This guide describes "biohacking" peptides (BPC-157, TB-500 and related "wellness peptides", plus grey-market and compounded copies of GLP-1 weight-loss drugs) and oral methylene blue as regulators, a poison centre and patient-safety bodies describe them, as of October 2026 (US FDA, Australian TGA, Blue Ridge Poison Center, ECRI/ISMP). It sets out the psychotherapist's own work alongside them: the psychotherapist never supplies, sells, prescribes, recommends or advises on these substances; the inventory in section 4 is the therapist's own work with a client who uses or is considering them.

What it is. "Biohacking" is a consumer self-optimisation movement in which people take substances, often bought online, to try to change body and brain function. Two strands are covered here:

Peptides. Short chains of amino acids promoted online for weight loss, muscle growth, injury recovery, anti-ageing, performance and immune support, often as injectable products. Named examples in regulator and patient-safety warnings include BPC-157, TB-500 (a thymosin beta-4 fragment), GHK-Cu, CJC-1295, Melanotan II, epitalon and others, and unapproved versions of GLP-1 drugs (semaglutide, tirzepatide, and the investigational retatrutide) [source: TGA peptides page; ECRI/ISMP 2026; FDA GLP-1 concerns page].
Methylene blue. A synthetic dye and prescription drug (FDA-approved for methaemoglobinaemia) now sold online as an oral "supplement", promoted by influencers for mitochondrial function, antioxidant effects, anti-ageing, mood, cognition ("nootropic") and jet lag [source: Blue Ridge Poison Center 2025; NPR/WFAE 2025].

Core idea of how change happens (as promoters hold it). Promoters claim that peptides "signal" tissues to repair, regenerate or burn fat, and that methylene blue improves how mitochondria produce cellular energy, so that the user becomes healthier, younger-acting, leaner or mentally sharper. These are attributed claims. [source: TGA; NPR/WFAE 2025]

Evidence status (one line each). BPC-157: 35 of 36 published studies were in animals, with no published phase 1 human safety data and no controlled human efficacy trials [source: ECRI/ISMP 2026]. TB-500: FDA has identified no human exposure data [source: FDA bulk substances safety risks page]. Oral methylene blue as a wellness product: laboratory, animal and small human studies only, described by researchers as preliminary [source: NPR/WFAE 2025]. Grey-market GLP-1 copies: not FDA-approved and not reviewed for safety, effectiveness or quality [source: FDA GLP-1 concerns page].

For the psychotherapist the core idea is different [synthesis]: change comes from the client making an informed, values-based decision about these products with accurate safety information from their prescriber or pharmacist, while the therapist works with the needs the products are meant to meet (control over ageing, body shape, performance, mood or energy) and with any health anxiety, body-image or eating-disorder features.

2. Framework

2a. How the method reaches clients (as sources describe it)

Promotion. Social media and influencers, wellness and longevity content, and websites that describe research findings in ways regulators read as therapeutic claims [source: TGA; FDA warning letter to Peptide Partners LLC, 2026; NPR/WFAE 2025].
Supply routes.
- Online vendors selling peptides labelled "for research use only" or "not for human consumption", with no prescription, pharmacist oversight or quality testing; FDA and TGA both state that this label does not change a product's legal status where it is marketed for human use [source: ECRI/ISMP 2026; FDA Peptide Partners letter; TGA].
- Compounding pharmacies and telehealth companies (GLP-1 copies; some peptides) [source: FDA GLP-1 concerns page; TGA].
- Personal importation [source: TGA].
- Oral methylene blue sold online as a supplement, often not listed in the federal supplement-label registry [source: NPR/WFAE 2025; Blue Ridge Poison Center 2025].
What a client experiences. Typically self-directed use following an online "protocol"; sometimes prescription through a telehealth service or clinic. Peptides are often injected by the user; methylene blue is swallowed and visibly turns urine, tongue and teeth blue [source: TGA; NPR/WFAE 2025]. No preparation, amounts or schedules are given in this guide.

2b. Regulation and licensing (one line each)

United States, peptides. FDA lists BPC-157, TB-500 and many other peptides among bulk substances whose nominations for compounding were withdrawn, citing immunogenicity, peptide-related impurities and limited or absent human safety data [source: FDA bulk substances safety risks page]. In April 2026 FDA announced removal of 12 peptides from its Category 2 ("significant safety concerns") list and scheduled Pharmacy Compounding Advisory Committee review (BPC-157, TB-500, KPV and MOTs-C on 23 July 2026); removal from Category 2 does not make a substance eligible for compounding [source: Goodwin 2026]. ECRI and ISMP state the reclassification came without new clinical evidence and is not a safety endorsement [source: ECRI/ISMP 2026]. The outcome of the July 2026 review [uncertain: not verified].
United States, "research peptides" sold to consumers. FDA treats them as unapproved new drugs when evidence shows intended human use, as in an August 2026 warning letter covering semaglutide, tirzepatide, retatrutide and other peptides and the reconstitution water sold with them [source: FDA Peptide Partners letter].
United States, GLP-1 copies. Compounded versions are not FDA-approved; salt forms of semaglutide have no known lawful basis for compounding; retatrutide and cagrilintide cannot be used in compounding; counterfeit Ozempic has been found in the supply chain [source: FDA GLP-1 concerns page].
United States, methylene blue. FDA-approved as a prescription treatment for methaemoglobinaemia; oral wellness products are sold online as supplements, not subject to FDA standards or testing, and their status as supplements is described as unclear [source: NPR/WFAE 2025; Blue Ridge Poison Center 2025].
Australia. Peptides are therapeutic goods under the Therapeutic Goods Act 1989; BPC-157, GHK-Cu, TB-500, retatrutide and CJC-1295 are unapproved; promoting unapproved peptides on social media or via influencers is likely to breach advertising law; a "research use only" label does not make supply lawful; practitioners who compound, prescribe or supply them must meet regulatory and AHPRA standards [source: TGA; RACGP newsGP 14 April 2026].
United Kingdom, EU and Canada. Status of these specific products [uncertain: not verified]; check the national medicines regulator (MHRA, national competent authorities, Health Canada).
Who practises it. Mostly self-use; also telehealth prescribers, compounding pharmacies, "med spa" or longevity clinics and online vendors [source: FDA GLP-1 concerns page; TGA; ECRI/ISMP 2026]. Med-spa involvement [uncertain: not verified].

2c. The psychotherapist's framework alongside it [synthesis]

No source sets out phases for psychotherapy alongside biohacking use. The following structure is the guide's own synthesis, built on the domain's standard alongside tasks.

Phase	Goal	Typical format	Move on when
1. Ask and record	Learn what is being used, from where, and why, without judgement	Part of intake and periodic review	Use (or non-use) is recorded and the client is still talking openly
2. Meaning and expectations	Understand hopes, explanatory model and what the product stands for	Woven into ongoing therapy	The client can name what they hope for and what would tell them it is not working
3. Informed decision and coordination	Client has accurate safety information from a prescriber or pharmacist and decides freely	Consent-based contact with doctor or pharmacist; decision conversation	Prescriber or pharmacist is informed (with consent) or the client has chosen not to involve them and the risk is documented
4. Risk monitoring	Recognise and respond to serotonin toxicity, injection complications, disordered eating, mania or worsening mood, financial or group pressure	Ongoing; brief check at each review	Continuous
5. Underlying work	Address health anxiety, body image, perfectionism, ageing fears, performance pressure	The main psychological treatment, cross-reference Domain II	Per the chosen treatment model

Phases overlap; risk (phase 4) overrides sequence at any point.

3. Guiding principles

Stay in scope. The therapist never supplies, sells, prescribes, recommends, endorses or advises on starting, stopping or changing any peptide, methylene blue or medicine; route every medicine question to the prescriber or pharmacist. Practical meaning: "That is a question for your doctor or pharmacist; I can help you prepare for that conversation." [synthesis; APA Ethics Code 2.01 Boundaries of Competence]
Ask routinely, without judgement. Clients often do not disclose; ECRI/ISMP urge clinicians to proactively counsel patients who may be using these products without disclosing it. Practical meaning: ask everyone, including about online and "research" products, in the same neutral tone as any medication question. [source: ECRI/ISMP 2026]
Know the one interaction that matters most for psychotherapy. Methylene blue can cause serotonin toxicity with serotonergic antidepressants; FDA cases involved SSRIs, SNRIs and clomipramine, with risk unclear for other tricyclics, MAOIs, trazodone, bupropion, mirtazapine, buspirone and others. Practical meaning: if a client on any psychiatric medicine mentions methylene blue, link them to their prescriber promptly. [source: FDA DSC 20 Oct 2011; Blue Ridge Poison Center 2025]
Respect autonomy, inform the decision. Adults may make choices the therapist disagrees with; the therapist's job is to support a free, informed choice, not to win an argument. Practical meaning: explore, give regulator-sourced facts only when invited or when risk demands, and avoid coercion. [synthesis; APA Ethics Code Principle E]
Attribute claims; do not argue biochemistry. Describe mitochondrial, "signalling" and anti-ageing claims as promoters' claims, with evidence status in one line. Practical meaning: "Promoters say...; regulators say...". [synthesis]
Unknown product, unknown risk. Regulators and testing data report unknown contents, wrong compound, wrong amount, contamination and non-sterility. Practical meaning: the label on a vial or bottle is not reliable information, so the therapist never reasons from it. [source: TGA; Mendias and Awan 2026 preprint]
Coordinate with consent. Share information with the client's doctor or pharmacist with the client's consent; disclose without consent only where law or valid purpose (e.g. preventing serious harm) allows. Practical meaning: get written consent early. [source: APA Ethics Code 4.05 Disclosures]
Look beneath the product. Biohacking often sits on ageing anxiety, body dissatisfaction, performance pressure, health anxiety or control needs. Practical meaning: the product is a doorway to the clinical work, not the target. [synthesis]
Screen for eating disorders around weight-loss products. GLP-1 copies and fat-loss peptides may be used to restrict. Practical meaning: screen sensitively when weight loss is a goal. [synthesis]
No conflicts of interest. The therapist never sells products, affiliate links, courses or "protocols", and declines roles where financial interests could compromise care. [source: APA Ethics Code 3.06 Conflict of Interest]
Report what should be reported. Adverse events go to the medicines regulator; illegal promotion to the regulator's breach or advertising route; children at risk to safeguarding. Practical meaning: know the routes before you need them (section 4.9). [source: FDA GLP-1 concerns page; TGA]

4. Intervention inventory

All interventions below are the psychotherapist's own work. None involves supplying, recommending, preparing or advising on any substance. Where no source sets out the procedure, it is marked [synthesis].

4.1 Routine, non-judgemental inquiry and recording

Purpose / when. Find out whether the client uses peptides, methylene blue, grey-market or compounded weight-loss injections or other "biohacking" products. Use at intake, at every medication review, when a client mentions energy, ageing, weight, fitness, "optimisation" or longevity content, and when there are unexplained physical symptoms. ECRI and ISMP specifically advise clinicians to counsel patients who may be using these products without disclosing it [source: ECRI/ISMP 2026].
Steps [synthesis].
1. Normalise: say that you ask everyone about supplements, online products and anything injected.
2. Ask open, then specific questions: what, from where (pharmacy, telehealth, clinic, website, gym contact, "research" seller), why, since when, who suggested it, and whether their doctor and pharmacist know.
3. Ask specifically about psychiatric and other medicines alongside, because of the methylene blue interaction (see 4.6).
4. Ask about any visible effects or problems (blue urine or tongue; injection-site problems; stomach upset; feeling unwell).
5. Record the product names as the client gives them, source, the client's stated reasons and whether prescribers are aware. Do not record or discuss amounts or schedules beyond what a prescriber may need.
6. Thank the client for telling you; signal that you will not judge or report them for personal use.
Example language (illustrative). "I ask everyone this: are you taking anything for health, energy, weight or ageing that isn't from your doctor, including things bought online or labelled for research?" / "Some people try peptides or methylene blue they've seen online. Is anything like that part of your routine?"
Watch for. Defensiveness or minimising ("it's just a supplement"); products described by code names; "research use only" sources (regulators say this label does not change legal status) [source: TGA; FDA Peptide Partners letter]; combination with antidepressants. Working when the client brings updates unprompted.

4.2 Exploring meaning, hopes, expectations and explanatory model

Purpose / when. Understand what the products mean to the client before any discussion of risk, so that later conversations address what matters to them. Use once use is disclosed or considered.
Steps [synthesis].
1. Ask what drew them: control over ageing or illness, body shape, athletic or cognitive performance, energy, distrust of medicine, identity as an "optimiser", belonging to an online or gym community, a trusted influencer.
2. Elicit their explanatory model in their own words (e.g. "my mitochondria are tired", "this repairs tendons"), without correcting it at this stage.
3. Ask about expectations: what change they expect, by when, and how they would know it is not working.
4. Ask what it would mean to stop or never start (loss, fear, giving up on a goal).
5. Reflect the underlying need and link it to therapy goals where the client agrees.
Example language (illustrative). "What were you hoping it would change for you?" / "If it worked perfectly, what would be different in a month?" / "What does being 'optimised' mean for you?"
Watch for. Fear of ageing or death, perfectionism, body dissatisfaction, performance pressure (work, sport), health anxiety, and grandiosity or escalating reward-seeking. Promoters' claims are often absorbed verbatim from influencers [source: NPR/WFAE 2025]; note the source of the belief. Working when the client talks about the need rather than only the product.

4.3 Sharing regulator and safety-body information, on request or when risk requires

Purpose / when. Give accurate, attributed information so that any decision is informed. Use when the client asks what you think, when they rely on a single influencer source, or when a known risk applies (e.g. antidepressants plus methylene blue).
Steps [synthesis].
1. Ask permission: "Would it help to hear what regulators have said?"
2. Share only what regulators and safety bodies state, attributed, in one or two sentences each. Examples: FDA and TGA say these peptides have not been evaluated for safety, quality or effectiveness; testing of grey-market products found wrong or absent compounds, inaccurate amounts and endotoxin contamination; FDA reports serotonin syndrome when methylene blue was given with some antidepressants [source: TGA; Mendias and Awan 2026 preprint; FDA DSC 2011].
3. Do not interpret the information into medical advice; say clearly that the prescriber or pharmacist is the person for decisions about substances and medicines.
4. Offer to help them prepare questions for the prescriber or pharmacist (4.5).
5. Check understanding and reaction; return to meaning (4.2) if the client feels criticised.
Example language (illustrative). "I'm not the right person to advise on substances, but I can tell you what the medicines regulator has published, if that's useful." / "The FDA says products labelled 'research use only' are still treated as drugs if they're sold for people to take."
Watch for. Reactance (the client hears control rather than information); the therapist drifting into telling the client what to take or stop (out of scope). Working when the client seeks the prescriber's or pharmacist's view.

4.4 Supporting an informed, values-based decision without coercion

Purpose / when. Help the client weigh using, continuing, pausing or not starting, in line with their own values, once they have accurate information. No published decision aid specific to these products was located [uncertain: not verified].
Steps [synthesis].
1. Clarify the decision and who else is involved (prescriber, partner, coach).
2. Elicit values: health, longevity, appearance, safety, money, honesty with their doctor, being a role model for children.
3. Lay out the options the client names, including talking to a prescriber about approved alternatives where relevant (e.g. FDA-approved GLP-1 medicines filled at a licensed pharmacy, as FDA advises) [source: FDA GLP-1 concerns page]; never suggest a specific product.
4. Explore what the client knows and does not know about each option (unknown contents, quality, interactions) and what they would want to find out from the prescriber.
5. Summarise the client's own reasons; let them decide; record the decision and that it was theirs.
6. Revisit when circumstances change (new medicine, pregnancy plans, symptoms).
Example language (illustrative). "Whatever you decide, I want it to be your decision, made with good information. What matters most to you here?" / "What would you need to know from your doctor before you decide?"
Watch for. The therapist's own disapproval leaking in; the client deciding to please the therapist; pressure from a coach, partner or online group. Working when the client can state the choice and their reasons, and has spoken to the prescriber or chosen not to and knows the risks they are accepting.

4.5 Coordinating with the client's doctor or pharmacist, with consent

Purpose / when. Ensure the people responsible for the client's medicines know about the products. Use whenever the client takes prescribed medicines (especially psychiatric medicines), has a medical condition, is pregnant or planning pregnancy, or reports symptoms. FDA advises patients to obtain GLP-1 drugs on prescription from their doctor and a state-licensed pharmacy and to talk to their doctor about dosing; ECRI/ISMP advise consulting a licensed clinician before any peptide therapy [source: FDA GLP-1 concerns page; ECRI/ISMP 2026].
Steps [synthesis].
1. Explain why: substances interact and the prescriber needs the whole picture.
2. Offer options: the client tells their doctor or pharmacist; the client takes a short written note; or, with written consent, the therapist contacts them.
3. In any contact, state facts only: the product name as the client gave it, the source as reported, the client's psychiatric medicines if known, and any symptoms. Do not offer opinions on dosing or management.
4. Record consent, what was shared and the response.
5. Without consent, share only where law or a valid purpose such as preventing serious harm permits [source: APA Ethics Code 4.05].
Example language (illustrative). "Would you be willing for your GP to know about this? I can help you work out what to say." / To a prescriber: "My client has consented to me letting you know they report taking an online methylene blue product alongside their antidepressant. I'm not in a position to advise on this and wanted you to be aware."
Watch for. Shame about telling the doctor; fear of being judged or refused a prescription; telehealth prescribers who did no screening (FDA warns about services that skip screening) [source: FDA GLP-1 concerns page]. Working when the prescriber or pharmacist is informed.

4.6 Recognising and responding to serotonin toxicity risk with methylene blue

Purpose / when. The highest-priority risk in a psychotherapy setting. Methylene blue is a potent MAO inhibitor and can cause serotonin toxicity in people taking serotonergic medicines [source: Blue Ridge Poison Center 2025]. FDA received reports of serious CNS reactions (serotonin syndrome) mostly with intravenous use during surgery in patients on serotonergic psychiatric medicines; cases occurred with SSRIs, SNRIs and clomipramine, risk with other psychiatric medicines is unclear, and the risk with oral use is unknown [source: FDA DSC 20 Oct 2011]. Serotonin toxicity can cause high blood pressure, diarrhoea, seizures and death [source: NPR/WFAE 2025]. Use whenever a client on any psychiatric medicine mentions methylene blue.
Steps [synthesis].
1. If the client reports methylene blue plus any psychiatric medicine and is currently well: tell them, attributing FDA, that this combination has been linked to a serious reaction; urge prompt contact with the prescriber or pharmacist that day; do not advise stopping or changing any medicine; record the conversation.
2. If the client is unwell now (for example confused, agitated, shaking, sweating heavily, feverish, with muscle twitching or stiffness, vomiting or diarrhoea, or seizure): treat as a medical emergency; call emergency services or arrange urgent medical assessment; tell responders what the client has taken. These features are general clinical knowledge, not taken from the cited sources [synthesis].
3. In the US, poison centres (1-800-222-1222) can advise on exposures [source: Blue Ridge Poison Center 2025]; elsewhere, use the national poisons information service [uncertain: not verified].
4. Also note: the poison centre advises asking about G6PD deficiency (risk of haemolysis) and family history [source: Blue Ridge Poison Center 2025]. If the client mentions G6PD deficiency, route to the prescriber.
Example language (illustrative). "The FDA has reported a serious reaction when methylene blue is taken with some antidepressants. I can't advise on your medicines, but this is something your prescriber needs to know about today. Can we call them now?"
Watch for. Clients who started an antidepressant after beginning methylene blue (or vice versa) without telling either prescriber; clients who have stopped an antidepressant on their own to take methylene blue (route to prescriber; do not advise). Working when the prescriber has been informed and the client knows the warning signs.

4.7 Recognising and responding to physical risks of injected peptides and GLP-1 copies

Purpose / when. Notice when a client may need medical care. TGA reports injectable peptide risks of contamination, infection and local tissue damage, and adverse events including severe allergic reactions needing adrenaline and hospitalisation, systemic inflammatory response syndrome and tendon or plantar-fascia injuries [source: TGA]. FDA has received adverse event reports, some requiring hospitalisation, from dosing errors with compounded semaglutide, with nausea, vomiting, diarrhoea, abdominal pain and constipation [source: FDA GLP-1 concerns page]. ECRI/ISMP cite a halted trial after a fatal cardiac event, case reports of melanoma and kidney dysfunction, and a death after intravenous use, across the wider "wellness peptide" group [source: ECRI/ISMP 2026]. Use when a client who injects products reports feeling unwell.
Steps [synthesis].
1. Ask about symptoms without examining: redness, swelling, heat or pus at a site; fever; breathing difficulty, swelling of face or throat, or collapse; persistent vomiting or abdominal pain; new pigmented skin lesions.
2. Emergency features (breathing difficulty, collapse, facial swelling) mean emergency services now.
3. Other symptoms mean same-day or prompt medical review; encourage the client to bring the product and packaging so clinicians know what was used.
4. Never comment on the amount, technique or schedule; never advise continuing or stopping.
5. Record and, with consent, inform the GP.
Example language (illustrative). "I can't tell you what's causing that, but swelling and fever after an injection need a doctor today. Would you take the vial with you so they can see what it was?"
Watch for. Minimising ("it's normal for the first week"), avoiding doctors out of shame or fear of legal trouble, shared vials or equipment in gym or online groups [synthesis]. Working when the client seeks care promptly.

4.8 Eating-disorder, body-image and muscle-dysmorphia screening around weight-loss and physique products

Purpose / when. GLP-1 copies are bought for weight loss; peptides are promoted for fat loss and muscle growth [source: TGA; FDA GLP-1 concerns page]. Self-sourced use, without prescriber screening, may mask or fuel restrictive eating or muscle dysmorphia [synthesis]. Use whenever weight, shape or physique is a motive.
Steps [synthesis].
1. Ask about eating patterns, compensatory behaviours, weight history, body checking and distress about shape, using a validated screening approach your service uses (e.g. per Domain II eating-disorder guidance).
2. Ask whether a prescriber assessed them before supply; FDA warns about telehealth providers who skip proper screening [source: FDA GLP-1 concerns page].
3. If there are restrictive, purging, orthorexic or muscle-dysmorphic features, or low weight, refer for medical assessment and to an eating-disorder pathway; inform the prescriber with consent.
4. Do not discuss weight targets, amounts or schedules.
Example language (illustrative). "Some people use these products when they feel very unhappy with their body or their eating. How has that been for you?"
Watch for. Rapid weight change, secrecy, rigid rules, distress at missed injections, vomiting framed as "side effects", adolescents obtaining products online. Working when the client engages with assessment.

4.9 Recognising wider risk: children, pregnancy, mental state, money and group pressure

Purpose / when. Respond to situations where use carries additional risk. Use whenever these features appear.
Steps and content.
- Children and adolescents. If a young person is being given or is obtaining injectables or methylene blue, or a child is being deprived of medical care, follow your safeguarding procedure; assess consent and capacity; involve parents or carers as appropriate and law permits; never name the child in any external material [synthesis].
- Pregnancy or planned pregnancy. Sources cited here do not address pregnancy [uncertain: not verified]; route promptly to the prescriber, midwife or obstetric team [synthesis].
- Mental state. Watch for mood elevation, sleeplessness, escalating "stacking" of products, or worsening depression after stopping an antidepressant independently; respond per usual psychiatric risk practice and inform the prescriber [synthesis].
- Financial exploitation and commercial pressure. Tiered "protocols", subscription telehealth, affiliate influencers and expensive coaching [synthesis]; FDA notes illegal online sellers and fraudulent compounded products naming non-existent pharmacies [source: FDA GLP-1 concerns page]. Explore spending and pressure to buy.
- Group pressure. Gym, sports, longevity or online communities that normalise injecting or ridicule doctors [synthesis]. Explore belonging needs and freedom to disagree.
Example language (illustrative). "How much is this costing you each month, and how do you feel about that?" / "What would happen in your group if you decided to stop?"
Watch for. Escalating cost, secrecy from partner, loss of other supports, pressure to recruit others. Working when the client can discuss these openly and seek help.

4.10 Health anxiety, optimisation anxiety and somatic presentations

Purpose / when. Some clients use biohacking to manage fears about illness, ageing, fatigue or cognitive decline, or for persistent bodily symptoms without explanation. Use when the pattern looks like health anxiety (repeated checking, reassurance-seeking, "protocol" escalation) or a somatic symptom presentation. Cross-reference Domain II for full protocols.
Steps [synthesis].
1. Formulate the cycle: trigger (symptom, age milestone, online content), threat appraisal, safety behaviour (new product, "stack", tracking), short-term relief, long-term maintenance.
2. Use established CBT approaches for health anxiety and somatic symptoms (Domain II): psychoeducation on the anxiety cycle, monitoring, reducing checking and reassurance-seeking, behavioural experiments, attention training, values work.
3. Treat product use as one possible safety behaviour without telling the client to stop it; any change to substances goes through the prescriber.
4. Address information diet: time on influencer content and its effect on anxiety.
Example language (illustrative). "It sounds as if each new product brings relief for a while, then the worry comes back. Shall we map that out together?"
Watch for. Substitution of one "protocol" with another; the therapist being drawn into debating mechanisms. Working when anxiety and checking reduce and the client's life widens.

4.11 Reporting routes

Purpose / when. Know where adverse events, illegal supply, misleading promotion and professional misconduct go. Use after an adverse event, when a client describes illegal promotion or supply, or when a health professional supplies unlawfully.
Routes.
- US adverse events and quality problems: FDA MedWatch (online or by fax); questions to the FDA CDER drug information line [source: FDA GLP-1 concerns page]. Poison centres for exposures [source: Blue Ridge Poison Center 2025].
- Australia: TGA "Report a breach" for counterfeit goods, illegal activity and non-compliant advertising; adverse event reporting to TGA; practitioner conduct to AHPRA [source: TGA; RACGP newsGP 2026].
- UK, EU, Canada: national medicines regulator (MHRA Yellow Card in the UK) and advertising regulator [uncertain: not verified].
- Professional misconduct: when informal resolution is not appropriate or fails and there is substantial harm, escalate to the relevant ethics or licensing body [source: APA Ethics Code 1.05].
- Children: local safeguarding or child protection services [synthesis].
Steps [synthesis]. Explain the route to the client; support them to report, or report yourself where you have direct knowledge and confidentiality permits; record what was reported.
Example language (illustrative). "You can report this to the medicines regulator, and you don't have to have done anything wrong to do that. Would you like help?"
Watch for. Client fear of legal consequences for personal use; balance reporting against confidentiality [source: APA Ethics Code 4.05].

4.12 Therapist's own boundaries and documentation

Purpose / when. Protect clients from conflicts of interest and scope drift. Always.
Steps.
1. Never sell, supply, recommend or share links, codes or "protocols" for any product [source: APA Ethics Code 3.06].
2. Stay within competence; refer medical questions [source: APA Ethics Code 2.01].
3. Do not take a second role (coach, investor, affiliate) with a client in this area [source: APA Ethics Code 3.05].
4. Include in informed consent to therapy that you ask about all substances and will encourage coordination with prescribers [source: APA Ethics Code 10.01].
5. Document disclosures, information given, consent to contact and decisions [synthesis].
Example language (illustrative). "I don't recommend or advise on products of any kind; my part is helping you think things through and making sure your doctor is in the loop."
Watch for. Personal interest in biohacking colouring the work; being asked for your own "stack". Working when the client is clear about your role.

5. Handling problems

None of the cited sources addresses psychotherapy alongside these products; all responses below are [synthesis] unless a source is named.

Client will not disclose or minimises. Return to routine, neutral inquiry (4.1); explain that you ask because of interactions with medicines, not to judge. Revisit at medication reviews. ECRI/ISMP note that patients may use these products without telling clinicians [source: ECRI/ISMP 2026].
Client asks "What should I take?" or "Is this dose OK?" Decline clearly and warmly; say it is outside your scope; offer to help them prepare questions for a prescriber or pharmacist (4.5). Never comment on amounts, sources or technique.
Client wants the therapist to endorse their protocol. Reflect the wish for validation; separate respect for the person from endorsement of a product; return to values (4.4).
Resistance or reactance to safety information. Stop informing; go back to meaning (4.2); ask permission before giving information again; use the client's own stated values as the reference point rather than the therapist's view.
Client distrusts doctors. Explore the history (dismissal, side effects, cost, discrimination); validate legitimate grievances; look for a prescriber or pharmacist they could trust; avoid becoming the substitute medical adviser.
Client on antidepressants starts methylene blue and refuses to tell the prescriber. Explain the FDA warning (4.6) and the reason for urgency; explore the fear behind refusal; document. If they become unwell, act as an emergency (4.6). Weigh confidentiality against serious-harm thresholds with supervision and local law [source: APA Ethics Code 4.05].
Non-adherence to prescribed psychiatric medicine in favour of biohacking. Do not argue for or against the medicine; inform the prescriber with consent; explore what the client hopes the product offers that the medicine does not; monitor mental state.
Overwhelm after learning risks (e.g. after reading about contamination). Ground, slow down, normalise; focus on one next step (contacting a doctor); watch for health-anxiety escalation (4.10).
Rupture: client feels judged or "reported". Name it, apologise for any part you played, clarify confidentiality and your role; repair before returning to risk topics.
Stuck: endless research, new products, no change in distress. Formulate as a safety-behaviour cycle (4.10); shift focus to the underlying fear and to values-based living.
Family conflict (partner or parent opposes use, or pressures use). Offer a joint session if appropriate; keep the decision with the person whose body it is, except for children, where safeguarding applies (4.9).
Client is a health professional or coach supplying others. Clarify that supply may be unlawful (TGA and FDA positions above) [source: TGA; FDA Peptide Partners letter]; explore; consider reporting duties where others are put at risk [source: APA Ethics Code 1.05].
Therapist's own interest or bias. Seek supervision if you personally use or strongly oppose these products and notice it affecting the work.

Harm account

What was actually done

Methylene blue with serotonergic medicines (2011). FDA reported cases of serious CNS reactions (serotonin syndrome) in patients taking serotonergic psychiatric medicines who were given methylene blue, mostly as an intravenous dye to visualise tissue during parathyroid surgery; cases involved SSRIs, SNRIs and clomipramine. FDA issued a drug safety communication on 26 July 2011 and updated it on 20 October 2011 [source: FDA DSC 20 Oct 2011].
Oral methylene blue as a wellness product (2020s). Social media promotes swallowing methylene blue bought online as a supplement for mitochondrial, anti-ageing and cognitive benefits; the Blue Ridge Poison Center (UVA Health) reported an increase in calls about oral exposures and warned that product concentration and purity vary [source: Blue Ridge Poison Center Sept 2025]. Many products are not listed in the federal supplement-label registry and their legal status as supplements is unclear [source: NPR/WFAE Dec 2025].
"Research use only" peptides sold for human use. Online vendors sell peptides labelled for research, with no prescription or quality testing, and sell sterile water to reconstitute them for injection. In an August 2026 warning letter FDA found that Peptide Partners LLC (Sarasota, Florida) sold semaglutide, tirzepatide, retatrutide, elamipretide, tesamorelin and bremelanotide products as unapproved new drugs, with website text describing research findings (including claims about cancer) that FDA read as evidence of intended human use [source: FDA Peptide Partners letter]. TGA reports the same pattern in Australia, often through social media and influencers [source: TGA].
Compounded and counterfeit GLP-1 drugs. Patients injected compounded semaglutide and tirzepatide from telehealth and compounding sources, sometimes measuring amounts incorrectly, sometimes after clinicians miscalculated; some received more than the approved label; counterfeit Ozempic entered the US supply chain; some products named pharmacies that did not exist [source: FDA GLP-1 concerns page].
Regulatory history of BPC-157 and related peptides. FDA identified immunogenicity, impurity and data-gap concerns and listed BPC-157 and TB-500 among nominated-and-withdrawn bulk substances; in April 2026 it announced removal of 12 peptides from Category 2 and an advisory committee review in July 2026 [source: FDA bulk substances page; Goodwin 2026]. The specific date of the original Category 2 placement (reported as 2023) [uncertain: not verified].

How it caused harm

Serotonin toxicity. Methylene blue is a potent MAO inhibitor; with serotonergic drugs it can cause serotonin toxicity [source: Blue Ridge Poison Center 2025], which can cause high blood pressure, diarrhoea, seizures and death [source: NPR/WFAE 2025]. Most at risk: people on SSRIs, SNRIs or clomipramine; risk with other psychiatric medicines is unclear; risk with oral use is unknown [source: FDA DSC 2011].
Haemolysis and methaemoglobinaemia. People with G6PD deficiency face oxidative stress and clinically significant haemolysis; higher exposures can cause paradoxical methaemoglobinaemia and haemolytic anaemia [source: Blue Ridge Poison Center 2025]. Milder effects include painful urination, discoloured urine, stomach upset and headache.
Unknown contents. Analysis of 6,285 consumer-submitted test results from grey-market peptides (a non-peer-reviewed preprint) found 41.6% to 71.1% failing purity, amount or identity criteria depending on the standard; identity failures (wrong or absent compound) were highest for TB-500 and CJC-1295; endotoxin was detectable in 15% of the small subset tested [source: Mendias and Awan 2026 preprint]. ECRI/ISMP report grey-market purity of only 5% to 75% and arsenic and lead above toxicity thresholds for injectable drugs [source: ECRI/ISMP 2026].
Injection-related and systemic harm. Infection, local tissue damage, severe allergic reactions needing adrenaline and hospitalisation, systemic inflammatory response syndrome and tendon or plantar-fascia injuries [source: TGA]. Across the wider group: a trial halted after a fatal cardiac event, melanoma and kidney dysfunction case reports, and a death after intravenous use [source: ECRI/ISMP 2026]; melanoma, posterior reversible encephalopathy syndrome and other serious events with Melanotan II [source: FDA bulk substances page].
GLP-1 dosing errors. Adverse events, some needing hospitalisation; as of 31 May 2026 FDA had 990 reports for compounded semaglutide and more than 730 for compounded tirzepatide, with likely underreporting [source: FDA GLP-1 concerns page].
Psychological and social harm [synthesis]. Missed or delayed medical care, interactions with untold prescribers, escalating spending, reinforcement of health or appearance anxiety and possible disordered eating.
Who is most at risk [synthesis, drawing on the sources above]: people on antidepressants; people with G6PD deficiency; people injecting products of unknown origin; people with eating disorders or body-image distress; adolescents buying online.

Recognising it today

Features and phrases. "Research use only" or "not for human consumption" products bought for personal use; product names given as codes; peptides plus reconstitution water; "stacks" and "protocols" from influencers; "mitochondrial", "longevity", "nootropic", "healing peptide" language; blue tongue, teeth or urine [source: FDA Peptide Partners letter; TGA; NPR/WFAE 2025].
Rebrandings. Compounded "semaglutide sodium" or "acetate" salt forms (FDA knows no lawful basis); unusually cheap telehealth GLP-1s; products arriving warm, damaged or without instructions [source: FDA GLP-1 concerns page]; regulatory reclassification described as approval (ECRI/ISMP say it is not a safety endorsement) [source: ECRI/ISMP 2026].
Red flags in a colleague's or service's practice [synthesis]. Selling or recommending peptides or methylene blue; affiliate links; advising clients to stop prescribed medicines; offering "protocols" outside scope; advising concealment from the GP.
How legitimate versions differ. FDA-approved methylene blue used by clinicians for methaemoglobinaemia; FDA- or TGA-approved peptide medicines (insulin, semaglutide, tirzepatide) prescribed after assessment and dispensed by a licensed pharmacy [source: NPR/WFAE 2025; TGA; FDA GLP-1 concerns page].

What to do instead and how to help those harmed

Safer alternatives (for the client to discuss with a prescriber). Approved medicines prescribed after assessment and filled by a licensed pharmacy, where a medical need exists [source: FDA GLP-1 concerns page; ECRI/ISMP 2026]. Psychological approaches for the underlying need: CBT for health anxiety, eating-disorder treatment, values-based work on ageing and performance (Domain II) [synthesis]. The therapist never recommends a specific product.
Assessment of affected clients [synthesis]. Physical symptoms (route to medical care); mental state, including after any change to psychiatric medicines; health anxiety; shame and self-blame; trust in clinicians; financial loss; group ties.
Treatment [synthesis]. Non-judgemental processing of what happened; work on self-blame and regret; rebuild a working relationship with a prescriber; treat health anxiety or eating-disorder features per Domain II; address financial stress.
Ethical, reporting and legal duties. Stay within competence and avoid conflicts of interest [source: APA Ethics Code 2.01, 3.06]; report adverse events and quality problems to FDA MedWatch or the national regulator, and illegal promotion or supply to TGA "Report a breach" or equivalent [source: FDA GLP-1 concerns page; TGA]; escalate professional misconduct [source: APA Ethics Code 1.05]; safeguard children [synthesis]; respect confidentiality limits [source: APA Ethics Code 4.05].

Sources

← Previous · XII-150Whole-body cryotherapy Next · XII-152 →Laetrile (vitamin B17)